Bionor Pharma (OSE: BIONOR) announced results of the final review of 136 patients phase IIb study data with therapeutic HIV vaccine, Vacc-4x seconds before market open. The company says that the data confirms a statistically significant 64% reduction of viral load
The possible new treatment option is obviously positive. Bionor starts to see a partner. The company says the data forms a basis for further trials. The Norwegian biopharmaceutical firm is studying three different options before pivotal study to reach market:
1. Revaccinating patients from phase 2b study to further reduce viral load
2. Combining Vacc-4x with Revlimid (Lenalidomide)
3. Vacc-4x and Vacc-c5 combination
After initial assessment over 18 months did not reveal the potential of the product candidate, Bionor was trading below 40 øre. Since then it has made a monstrous recovery and some could have taken profits from a ten bagger today. There have frequently been market rumours with the stock and they have more often than not proven to be true. Today Bionor popped over 60% within the first 30 minutes but has tamed somewhat since then to trade up 36% at 3.45 NOK.
No comments:
Post a Comment